{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:48:24Z","timestamp":1767134904820,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006552","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000}}],"reference-count":58,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006552.pub2","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T15:08:06Z","timestamp":1239808086000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rituximab as maintenance therapy for patients with follicular lymphoma"],"prefix":"10.1002","author":[{"given":"Liat","family":"Vidal","sequence":"first","affiliation":[{"name":"Beilinson Campus, Rabin Medical Center; Department of Internal Medicine E; 39 Jabotinsky Street Petah-Tiqva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[{"name":"Beilinson Campus, Rabin Medical Center; Department of Medicine E; 39 Jabotinsky Street Petah-Tiqva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[{"name":"Beilinson Campus, Rabin Medical Center; Department of Medicine E; 39 Jabotinsky Street Petah-Tiqva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[{"name":"Rabin Medical Center; Institute of Hematology; Petah-Tikva Israel 49100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"issue":"13","key":"10.1002\/14651858.CD006552.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD006552.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD006552.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD006552.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Hochster HS Weller E Gascoyne RD Ryan TS Habermann TM Gordon LI Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B Blood (ASH Annual Meeting Abstracts) 2005 Abstract 349","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Hochster HS Weller E RyanT Habermann TM Gascoyne R Frankel SR Horning S Eastern Cooperative Oncology Group Cancer and Leukemia Group B Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) Journal of Clinical Oncology (ASCO Annual Meeting Proceedings) 2004 Abstract 6502","DOI":"10.1200\/jco.2004.22.90140.6502"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Hochster HS Weller E Gascoyne RD Ryan T Habermann TM Gordon LI Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG\/CALGB intergroup E1496 trial Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 2007 8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004"},{"issue":"10","key":"10.1002\/14651858.CD006552.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00277-002-0548-2","article-title":"Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study","volume":"81","author":"Oers","year":"2002","journal-title":"Annals of Hematology"},{"issue":"10","key":"10.1002\/14651858.CD006552.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Oers","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0010|cit10","unstructured":"Baltasar SA Tripp FV Baez ED Rivas S Duque J Garces O CNOP vs. CNOP-rituximab vs. rituximab alone as first-line therapy for indolent non-Hodgkin lymphoma (INHL): Preliminary results Blood 2003 Abstract 4941"},{"issue":"2","key":"10.1002\/14651858.CD006552.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2006.10.005","article-title":"Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario","volume":"33","author":"Cheung","year":"2007","journal-title":"Cancer Treatment Reviews"},{"issue":"2 Suppl 6","key":"10.1002\/14651858.CD006552.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.32749","article-title":"Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Seminars in oncology","volume":"29","author":"Coiffier","year":"2002","journal-title":"Seminars in Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006552.pub2-BIB0013|cit13","first-page":"544","article-title":"Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL","volume":"3","author":"Fisher","year":"2005","journal-title":"Clinical Advances in Hematology & Oncology: H&O"},{"issue":"10","key":"10.1002\/14651858.CD006552.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD006552.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ctrv.2005.09.010","article-title":"Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III\/IV follicular lymphoma","volume":"31","author":"Ghielmini","year":"2005","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0145-2126(06)80005-6","article-title":"Patient benefits of maintenance immunotherapy","volume":"30 Suppl 1","author":"Ghielmini","year":"2006","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1002\/14651858.CD006552.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Annals of Hematology"},{"issue":"15","key":"10.1002\/14651858.CD006552.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1 Suppl 2","key":"10.1002\/14651858.CD006552.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/sonc.2003.50024","article-title":"Rituximab plus chemotherapy in follicular and mantle cell lymphomas","volume":"30","author":"Hiddemann","year":"2003","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(06)80001-9","article-title":"Rituximab maintenance therapy in follicular lymphoma comes of age","volume":"30 Suppl 1","author":"Hiddemann","year":"2006","journal-title":"Leukemia Research"},{"issue":"5","key":"10.1002\/14651858.CD006552.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD006552.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1093\/jnci\/djj156","article-title":"Fourth biannual report of the Cochrane Haematological Malignancies Group","volume":"98","author":"Kober","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Lepp\u00e4 S Linna M Nyman H Taimela E Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL) Blood (ASH Annual Meeting Abstracts) 2006 Abstract 3337","DOI":"10.1182\/blood.V108.11.3337.3337"},{"issue":"4","key":"10.1002\/14651858.CD006552.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"6 Suppl 12","key":"10.1002\/14651858.CD006552.pub2-BIB0025|cit25","first-page":"37","article-title":"Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma","volume":"27","author":"McLaughlin","year":"2000","journal-title":"Seminars in Oncology"},{"issue":"11","key":"10.1002\/14651858.CD006552.pub2-BIB0026|cit26","first-page":"1472","article-title":"Rituxan delays disease progression in indolent non-Hodgkin's lymphoma","volume":"16","year":"2002","journal-title":"Oncology (Williston Park)"},{"issue":"3-4","key":"10.1002\/14651858.CD006552.pub2-BIB0027|cit27","first-page":"106","article-title":"[Milestone in healing fatal indolent lymphoma]","volume":"42","year":"2004","journal-title":"Krankenpflege Journal"},{"issue":"10","key":"10.1002\/14651858.CD006552.pub2-BIB0028|cit28","first-page":"1316","article-title":"Rituximab maintenance stretches progression-free survival in patients with indolent NHL","volume":"18","year":"2004","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1002\/14651858.CD006552.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","article-title":"Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma","volume":"97","author":"Ogura","year":"2006","journal-title":"Cancer Science"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Rubio-Martinez A Recasens V Giraldo P Maintenance treatment with rituximab in follicular NHL Blood (ASH Annual Meeting Abstracts) 2006 Abstract 4702","DOI":"10.1182\/blood.V108.11.4702.4702"},{"issue":"1 Suppl 2","key":"10.1002\/14651858.CD006552.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/sonc.2002.30144","article-title":"Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone","volume":"29","author":"Sarris","year":"2002","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0032|cit32","unstructured":"Contact information: M Schultz A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with follicular lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy http:\/\/clinicaltrials.gov\/ct\/show\/NCT00394836?order=1"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0145-2126(06)80004-4","article-title":"Safety of rituximab maintenance therapy in follicular lymphomas","volume":"30 Suppl 1","author":"Solal-Celigny","year":"2006","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Tomas JF Montalban C Martinez-Lopez J Paz J Canales M Diaz-Mediavilla J Induction with fludarabine, cyclophosphamide and rituximab followed by maintenance with rituximab: Results of a prospective study in 75 patients (LNHF-03) Blood (ASH Annual Meeting Abstracts) 2006 Abstract 2762","DOI":"10.1182\/blood.V108.11.2762.2762"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Witzens-Harig M Hensel M Neben K Benner A Schmier JW Dreger P Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin-lymphoma - First interim results of a prospective randomised phase II study Blood (ASH Annual Meeting Abstracts) American Society of Hematology 2005 Abstract 2454","DOI":"10.1182\/blood.V106.11.2454.2454"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Witzens-Harig M Hensel M Schmier JW Neben K Benner A Dreger I Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study Journal of Clinical Oncology (ASCO Annual Meeting Proceedings Part I) 2006 Abstract 17524","DOI":"10.1200\/jco.2006.24.18_suppl.17524"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Witzens-Harig M Hensel M Schmier JW Neben K Benner A Dreger P Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin-lymphoma - Results of a multicenter prospective randomised phase II study Blood (ASH Annual Meeting Abstracts) 2006 Abstract 4704","DOI":"10.1182\/blood.V108.11.4704.4704"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Witzens-Harig M Hensel M Schmier JW Neben K Benner A Kramer A Ho AD Rituximab maintenenance therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma first interim results of a prospective randomised phase II study 10th Congress of the European Hematology Associasion, Stockholm, Sweden 2005","DOI":"10.1182\/blood.V106.11.2454.2454"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0039|cit39","unstructured":"Rituximab in treating patients with newly diagnosed stage II, stage III, or stage IV follicular non-Hodgkin's lymphoma www.cancer.gov\/cancer_information\/pdq date accessed 30.1.07"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0040|cit40","unstructured":"Combination chemotherapy plus peripheral stem cell transplantation with or without rituximab in treating patients with relapsed non-Hodgkin's lymphoma National Cancer Institute"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0041|cit41","unstructured":"Primary investigators: Pettengell R Linch DC Phase III randomized study of rituximab purging and maintenance with peripheral blood stem cell transplantation in patients with relapsed or resistant follicular non-Hodgkin's lymphoma undergoing high-dose chemotherapy"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0042|cit42","unstructured":"Principal Investigator: GA Salles Groupe d'Etude des Lymphomes de l'Adulte Primary rituximab and maintenance, Study ID Number: PRIMA"},{"issue":"11","key":"10.1002\/14651858.CD006552.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"Abstract 3420","DOI":"10.1182\/blood.V110.11.3420.3420","article-title":"Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab extended schedule or re-treatment trial (RESORT)","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD006552.pub2-BIB0044|cit44","first-page":"395","article-title":"ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma","volume":"3","author":"Williams","year":"2004","journal-title":"Current Hematology Reports"},{"issue":"5","key":"10.1002\/14651858.CD006552.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.82.21.7439","article-title":"Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18","volume":"82","author":"Cleary","year":"1985","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD006552.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0052|cit52","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]","author":"Higgins","year":"2006"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/11.suppl_1.S137","article-title":"Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series","volume":"11","author":"Lopez-Guillermo","year":"2000","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006552.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Schulz H Skoetz N Bohlius J Trelle S Kober T Greb A Engert A Blood (ASH Annual Meeting Abstracts) 2005 351","DOI":"10.1182\/blood.V106.11.351.351"},{"issue":"5","key":"10.1002\/14651858.CD006552.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006552.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:00:59Z","timestamp":1628532059000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006552.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006552.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}